Saturday Feb 11 | CiteULike
Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial
Objective: Since cholinergic deficits are prominent in dementia with Lewy bodies , we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase II trial.
New Alzheimers' Dementia drug for possible cure may trump invasive options
The race to find a complete cure has brought news over the last two years of a new safe and non-invasive claim of a wonder drug created from P7C3 that has been successful in treating rats.
Alzheimer's treatment sees major setback
In a major setback for patients and doctors, drugmakers Pfizer Inc. and Medivation Inc.
Abstract P210: Cardiovascular Safety of Dementia Drugs Among Medicare ...
Background: A recent randomized clinical trial raised a concern about the safety of rivastigmine, one of the drugs used to treat dementia.
Pfizer, Medivation end drug development deal
In a major setback for patients and doctors, drugmakers Pfizer Inc. and Medivation Inc.
Also on Topix